Pacific Source: Medicare Advantage plans: Locations, plans, and costs

PacificSource Medicare was founded in Oregon in 1933 as a not-for-profit company, offers Medicare Advantage plans, and has more than 300,000 members throughout the Northwest.

According to the Kaiser Family Foundation (KFF), Medicare-approved insurance companies, such as PacificSource, provided Advantage plans to more than 24 million US citizens in 2020.

This article looks at the PacificSource Advantage plans and availability. It also looks at the coverage, benefits, and costs.

We may use a few terms in this piece that can be helpful to understand when selecting the best insurance plan:

  • Deductible: This is an annual amount that a person must spend out of pocket within a certain time period before an insurer starts to fund their treatments.
  • Coinsurance: This is a percentage of a treatment cost that a person will need to self-fund. For Medicare Part B, this comes to 20%.
  • Copayment: This is a fixed dollar amount that an insured person pays when receiving certain treatments. For Medicare, this usually applies to prescription drugs.

PacificSource offers several Medicare Advantage plans, including Health Maintenance Organization (HMO), Health Maintenance Organization Point of Service (HMO-POS), and Preferred Provider Organization (PPO).

HMO plans

PacificSource HMO plans include Medicare Essentials 2 without Part D prescription drug coverage and MyCare Rx 40 including Part D.

When a person enrolls in an HMO plan, they agree to use the plan’s network of healthcare providers. They also choose a primary care doctor from within the network, who then coordinates health services and referrals to specialists.

If a person wants to use a healthcare provider from outside the network, they may have more costs, except in a medical emergency.

Medicare Essentials 2 (HMO) plan

This plan is available in certain counties in Oregon. In 2021, the monthly premium and the annual deductible are both zero, while the out-of-pocket maximum expense is $5,500. A person must use in-network providers.

My Care Rx 40 (HMO) plan

This plan is available in certain counties in Oregon.
The monthly premium in 2021 is zero. Out-of-pocket expenses in 2021 have an annual maximum of $4,950, and a person must use in-network providers.

HMO-POS plans

PacificSource HMO-POS plans include Medicare Essentials Choice Rx 14, and MyCare Choice Rx 24, both of which include prescription drugs (Part D) coverage.

With HMO-POS plans, people have the freedom to use healthcare services outside of their plan’s network. However, they must pay a higher copay or coinsurance to do so.

Medicare Essentials Choice Rx 14 plan (HMO-POS) plan

This plan is available in certain counties in Oregon.
In 2021, the monthly premium is $99.00 and the in-network out-of-pocket maximum is $5,500.

2021 MyCare Choice Rx 24 (HMO-POS) plan

This plan is available in certain counties in Idaho.
The monthly premium in 2021 is $35. Out-of-pocket expenses have an annual maximum of $5,500 in 2021 for in-network providers and no maximum for out-of-network services.

PPO plans

PacificSource PPO plans include Explorer 12 without the prescription drug (Part D) cover and Explorer Rx4, including Part D prescription drug coverage.

These

Read more

Asia Pacific Laser Therapy Market Forecast to 2027

The Asia Pacific laser therapy market is expected to reach US$ 768. 52 million by 2027 from US$ 348. 67 million in 2019; it is estimated to grow with a CAGR of 10. 5% from 2020 to 2027. The laser therapy market in Asia Pacific grows substantially due to growing medical applications of laser therapy and technological developments in laser therapies.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Laser Therapy Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type ; Application ; End User, and Geography” – https://www.reportlinker.com/p05978827/?utm_source=GNW
However, the high prices of laser therapy and devices hinder the growth of the market.

Laser therapy, a non-invasive medical procedure, uses the light of a specific wavelength to treat various diseases.This procedure is used to remove tumors or abnormal cell growth, perform hair and skin treatments, remove kidney stones, and repair a detached retina.

In medicine, the laser allows surgeons to work at a high level of precision by focusing on a definite area, and this process creates lesser damage than the traditional methods of surgery. The process of laser therapy is however costly and may require repetitive visits to the surgeon.

Various medical device manufacturers and start-ups introduce the latest technologies in the market and the availability of various advanced products allows medical professionals to improve patients’ health by enhancing their treatment efficiency. For instance, in February 2020, IRIDEX Corporation, a manufacturer of ophthalmic laser-based medical products, launched an upgraded second-generation version of MicroPulse P3 device to treat glaucoma, and the upgrades made to the device are expected to substantially reduce intraocular pressure suitable for glaucoma patients without incisions.

Furthermore, in June 2020, Cynosure launched Elite iQ Aesthetic Workstation for laser hair removal and skin revitalization in Australia, allowing faster treatment with higher max energy compared with previous generation devices.Moreover, in February 2019, GakSung introduced the Laser Queen, a low-level laser and LED therapy known as photon light therapy, in India to treat a variety of conditions.

Thus, the consistent technological developments through the launch of new products in the market augment the growth of the laser therapy market in Asia Pacific.

China, Japan, India, Australia, and South Korea are the most affected countries due to the increasing number of COVID-19 cases and the associated deaths.Manufacturers and suppliers of medical devices are shifting their focus from regular laser therapy devices to the development and supply of COVID-19 essentials and medical devices used for respiratory issues.

This scenario adversely impacts the dermatology & cosmetic and minimally invasive therapies performed with laser devices.

Based on type, in 2019, the diode segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period.This segment witnesses a lucrative growth owing to its rapid adoption in photodynamic treatments and aesthetic procedures.

Additionally, the diode laser is used for processes such as incision, hemostasis, and coagulation. Moreover, the implementation of diode laser causes minimal

Read more

The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019

The market is estimated to grow with a CAGR of 9. 6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Liposome Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product ; Technology ; Application, and Country” – https://www.reportlinker.com/p05978829/?utm_source=GNW
However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years.

Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquine diphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes.

Research and development (R&D) in liposomal drug delivery systems are increasing across the world due to the increasing prevalence of chronic disease.Drug delivery is the process of dispensing a pharmaceutical compound to attain a therapeutic effect in humans.

Liposomal drug delivery offers multiple advantages such as better pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity making these delivery systems ideal for patients suffering from various chronic conditions.

Death among the population worldwide has increased due to cancer.The targeted drug delivery system delivers the drug in a controlled manner at a preselected bio site.

Nanotechnology-based delivery systems are making a crucial impact on cancer treatment, and the polymers play a key role in the development of Nano particulate carriers for cancer therapy.Some of the major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of the drug, and many more.

The liposomal carriers used in nanotechnology drug delivery systems are likely to experience rapid adoption, which in turn is propelling the market growth.

As per the data provided by, European Society for Medical Oncology, China estimated there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer the most common cancer and the leading cause of cancer death. With high incidences and mortality, cancer is the leading cause of death in China and

Read more

The Asia Pacific pulmonary devices market is expected to reach US$ 8,196.82 million by 2027 from US$ 3,661.53 million in 2019

The market is estimated to grow at a CAGR of 10. 6 % during 2019–2027. The growth of the pulmonary devices market in Asia Pacific is attributed to the increasing prevalence of respiratory diseases and growing number of COVID-19 cases.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Pulmonary Devices Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type ; Application ; and End User and country” – https://www.reportlinker.com/p05978832/?utm_source=GNW
Factors such as unfavorable reimbursement scenario associated with the pulmonary device are likely to restrain the growth of the market.

Additionally, strategic activities by manufacturers and increasing preference of home care products are likely to fuel the growth of the pulmonary devices market during the forecast period.

Pulmonary or respiratory devices are used to remove mucus and secretions from the respiratory tract. These medical devices are focused on diagnosis, control, treatment, management, and evaluation of the problems associated with respiratory tract.

The higher prevalence of respiratory disorder is mainly due to the decrease in size of the upper airway lumen in aging population.Millions of people suffer from various respiratory diseases; lung diseases are the most common medical conditions.

Smoking, genetic factors, and infections are among the common factors responsible for respiratory diseases. Medical conditions such as asthma and chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, and lung cancer are among the significant public health burdens.

According to a new Tulane University study published in The Lancet, chronic obstructive pulmonary disease (COPD) is widespread in China with 8.6% of the country’s adult population, i.e. almost 100 million people suffering from the chronic lung disease. Additionally, among India’s 1.31 billion people, about 6% of children and 2% of adults have asthma.

The patients suffering with these respiratory disorders commonly experience difficulty in breathing.Thus, the availability of various pulmonary devices has helped improve the survival rates of the patients suffering from abovementioned medical conditions.

The rising demand for various therapeutic devices among patients with respiratory disorders is expected to augment the growth of the market during the forecast period.

Asia Pacific countries are expected to witness massive challenges due to increasing COVID-19 cases.To manage the COVID-19 outbreak and provide efficient treatment to patients in the region, local medical device companies are ramping up the production of alternative respiratory systems in the Asian countries.

The governments in India and Australia, among others are taking initiative to fulfill the demand of oxygen during COVID-19 pandemic. Thus, the development of these solutions is likely to create a positive impact on market growth in the Asian region.

In 2019, the therapeutic devices segment held the largest share in the market and is expected to retain its dominance till 2027.The multi-modal and multi-functional use of therapeutic devices for a wide range of pulmonary diseases is expected to account for the growth of the therapeutic devices segment over the coming years.

On the other hand, the consumables and accessories segment is expected to witness fastest growth

Read more

Goldie Hawn focuses on fitness as she pedals around Pacific Palisades in an athletic black ensemble

Goldie Hawn focuses on fitness as she pedals around Pacific Palisades wearing athletic black ensemble

She’ll soon deck the halls as Mrs. Claus in the return of The Christmas Chronicles 2.

But Goldie Hawn was focused on her fitness as she pedaled around the Pacific Palisades neighborhood of Los Angeles on Sunday afternoon. 

The 74-year-old actress rocked an all-black ensemble while soaking up the sun as she traveled around town on two wheels. 

Out and about: Goldie Hawn was focused on her fitness as she pedaled around the Pacific Palisades neighborhood of Los Angeles on Sunday afternoon

Out and about: Goldie Hawn was focused on her fitness as she pedaled around the Pacific Palisades neighborhood of Los Angeles on Sunday afternoon

Goldie looked ready for a brisk workout wearing a black tank top sports bra with matching leggings.

Peeks of her bright blonde hair peered out from underneath a white helmet and she wore silver framed sunglasses.

Hawn tucked what appeared to be face mask into her top as she rode a pearl white bicycle through the streets. 

Biker: The 74-year-old actress rocked an all-black ensemble while soaking up the sun as she traveled around town on two wheels

Biker: The 74-year-old actress rocked an all-black ensemble while soaking up the sun as she traveled around town on two wheels

Chic: Goldie looked ready for a brisk workout wearing a black tank top sports bra with matching leggings

Chic: Goldie looked ready for a brisk workout wearing a black tank top sports bra with matching leggings

Hawn will reprise her role as Santa’s leading lady in the upcoming Netflix sequel which will be released on Nov. 25.

In the first official trailer, ‘true believer’ teenager Kate Pierce (Darby Camp) and her pal Jack (Jahzir Bruno) find themselves unexpectedly transported to the North Pole during a family vacation with their parents. 

Oscar-nominated producer Chris Columbus (Harry Potter, Home Alone) directed and co-wrote the merry sequel with The Christmas Chronicles screenwriter Matt Lieberman.

Tis the season: Hawn will reprise her role as Santa's leading lady in the upcoming Netflix sequel which will be released on Nov. 25

Tis the season: Hawn will reprise her role as Santa’s leading lady in the upcoming Netflix sequel which will be released on Nov. 25

Adventure: In the first official trailer, 'true believer' teenager Kate Pierce (Darby Camp) and her pal Jack (Jahzir Bruno) find themselves unexpectedly transported to the North Pole during a family vacation with their parents

Adventure: In the first official trailer, ‘true believer’ teenager Kate Pierce (Darby Camp) and her pal Jack (Jahzir Bruno) find themselves unexpectedly transported to the North Pole during a family vacation with their parents

While TCC2 features Judah Lewis, Kimberly Williams-Paisley, and Tyrese Gibson, Goldie’s real-life son Oliver Hudson will not be back as deceased dad Doug Pierce in flashbacks.

The 2018 original flick managed to score an eye-popping 20 million views in its first week of streaming, despite having a 67% Rotten Tomatoes rating.

‘Kurt has never had that many people see one of his movies in the first week ever,’ Netflix CCO Ted Sarandos told Business Insider in 2018.

‘That’s a testimony to what we can bring to the market for storytellers today that we couldn’t have 10 years ago…If every one of those was a movie ticket purchase, that’s a $200M opening week.’

'Kurt has never had that many people see one of his movies in the first week ever,' Netflix CCO Ted Sarandos told Business Insider in 2018

‘Kurt has never had that many people see one of his movies in the first week ever,’ Netflix CCO Ted Sarandos told Business Insider in 2018

Advertisement

Source Article

Read more